Your browser doesn't support javascript.
loading
Profiling and Leveraging Relatedness in a Precision Medicine Cohort of 92,455 Exomes.
Staples, Jeffrey; Maxwell, Evan K; Gosalia, Nehal; Gonzaga-Jauregui, Claudia; Snyder, Christopher; Hawes, Alicia; Penn, John; Ulloa, Ricardo; Bai, Xiaodong; Lopez, Alexander E; Van Hout, Cristopher V; O'Dushlaine, Colm; Teslovich, Tanya M; McCarthy, Shane E; Balasubramanian, Suganthi; Kirchner, H Lester; Leader, Joseph B; Murray, Michael F; Ledbetter, David H; Shuldiner, Alan R; Yancoupolos, George D; Dewey, Frederick E; Carey, David J; Overton, John D; Baras, Aris; Habegger, Lukas; Reid, Jeffrey G.
Afiliación
  • Staples J; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Maxwell EK; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Gosalia N; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Gonzaga-Jauregui C; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Snyder C; Rochester Institute of Technology, Rochester, NY 14623, USA.
  • Hawes A; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Penn J; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Ulloa R; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Bai X; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Lopez AE; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Van Hout CV; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • O'Dushlaine C; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Teslovich TM; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • McCarthy SE; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Balasubramanian S; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Kirchner HL; Geisinger Health System, Danville, PA 17822, USA.
  • Leader JB; Geisinger Health System, Danville, PA 17822, USA.
  • Murray MF; Geisinger Health System, Danville, PA 17822, USA.
  • Ledbetter DH; Geisinger Health System, Danville, PA 17822, USA.
  • Shuldiner AR; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Yancoupolos GD; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Dewey FE; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Carey DJ; Geisinger Health System, Danville, PA 17822, USA.
  • Overton JD; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Baras A; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Habegger L; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
  • Reid JG; Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA. Electronic address: jeffrey.reid@regeneron.com.
Am J Hum Genet ; 102(5): 874-889, 2018 05 03.
Article en En | MEDLINE | ID: mdl-29727688
Large-scale human genetics studies are ascertaining increasing proportions of populations as they continue growing in both number and scale. As a result, the amount of cryptic relatedness within these study cohorts is growing rapidly and has significant implications on downstream analyses. We demonstrate this growth empirically among the first 92,455 exomes from the DiscovEHR cohort and, via a custom simulation framework we developed called SimProgeny, show that these measures are in line with expectations given the underlying population and ascertainment approach. For example, within DiscovEHR we identified ∼66,000 close (first- and second-degree) relationships, involving 55.6% of study participants. Our simulation results project that >70% of the cohort will be involved in these close relationships, given that DiscovEHR scales to 250,000 recruited individuals. We reconstructed 12,574 pedigrees by using these relationships (including 2,192 nuclear families) and leveraged them for multiple applications. The pedigrees substantially improved the phasing accuracy of 20,947 rare, deleterious compound heterozygous mutations. Reconstructed nuclear families were critical for identifying 3,415 de novo mutations in ∼1,783 genes. Finally, we demonstrate the segregation of known and suspected disease-causing mutations, including a tandem duplication that occurs in LDLR and causes familial hypercholesterolemia, through reconstructed pedigrees. In summary, this work highlights the prevalence of cryptic relatedness expected among large healthcare population-genomic studies and demonstrates several analyses that are uniquely enabled by large amounts of cryptic relatedness.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicina de Precisión / Exoma Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Am J Hum Genet Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicina de Precisión / Exoma Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Am J Hum Genet Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos